KYNB · Kyntra Bio, Inc.
Market Cap
$21.38M
Shares
4.05M
Volume · Oct 20
13.55K
Avg daily vol (3M)
19.56K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.28
Open$5.27
Day$5.26–5.45
52W close$4.85–11.18
Avg vol 30d27K
Short int100K · 2.5% float · 3.7d
Short vol16%
Last earningsAug 13, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Nov 14, 2026
Est · unconfirmed
· in 4 wks
filed Aug 13, 2026
call held Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$4.62M
Trailing 12 months
Net income (TTM)
$183.19M
Trailing 12 months
Revenue growth YoY
-209.3%
Year over year
Operating margin
-1,089.8%
Trailing 12 months
P / E (TTM)
0.1
Trailing earnings · reciprocal yield 858.0%
FCF yield
-193.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.1%
Year over year · more shares
Price change (1Y)
-49.1%
Trailing year
Short interest
2.5%
Latest settlement · 3.7 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−27%
below
Price vs 50-day avg
−25%
below
RSI (14)
30
oversold
MACD trend
Negative
52-week position
7%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−27%
trailing
6-month return
−25%
trailing
YTD return
−40%
this year
Relative strength
−33%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $7 — 200d above 50d
Institutional flow
Distributing
-15% holders QoQ · +1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.47% of float · ▼ -0.7% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
28 holders — near 1-yr low, contrarian setup
Squeeze score
39
low risk · 0–100
Fundamentals
Revenue growth
−78%
Y/Y
EPS growth
+482%
Y/Y
Free cash flow
$-4.8M
Valuation
P/E 0.1
below peers
Quant / Vol
risk profile
Volatility
53%
annualized · 1-yr
Max drawdown
−57%
past year
ATR
7.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Nov 6, 2023
Total annualized expenses reduction
· as a result of cost reduction plan
$120M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−27%
Bearish
Price vs 50-day avg
−25%
Bearish
RSI (14)
30
Neutral
MACD trend
Negative
Bearish
52-week position
7%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $7 › 200d $7 — 200d above 50d
Institutional flow
Distributing
-15% holders QoQ · +1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.47% of float · ▼ -0.7% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
28 holders — near 1-yr low, contrarian setup
Price context
position in its 52-week range
Range low $5
Now $5 · 7%
Range high $11
vs 200-day avg -27%
vs 50-day avg -25%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KYNB
this stock
Kyntra Bio, Inc.
|
$21.38M | -39.9% | -78.3% | 0.1 | 2.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +13.5% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +720.9% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +4.6% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.50B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KYNB | -10.1% | -27.5% | -25.1% | -20.6% | -39.9% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | -8.9% | -26.9% | -33.2% | -21.4% | -52.6% |